Go to Page # Page of 24

Oncology Drug Development and Value-Based Medicine

 Brian Huber PhD, John Doyle
  20th-Oct-2017
Description: An explosion of innovative science, sustained R&D investment and the clinical successes of a new wave of targeted therapies have transformed the oncology landscape. Hopes for understanding and controlling lethal cancers have never been higher, yet the challenges of bringing a product to market and achieving optimal market success remain undiminished. Clinical proof – once sufficient foundation for product success in oncology – today must be complemented with compelling demonstration of treatment “value.” In this paper, John Doyle and Brian Huber argue the intrinsic need to redefine the clinical trial process to ensure that appropriate data are generated throughout the clinical trial process to support the overall pharmacoeconomic value of a new drug and meet a future demand for value-based medical practices.
Views: 494
Domain: Medical
Category: Biotech/Pharma
Contributing Organization: QuintilesIMS
 ‐ More of their Presentations
Maxims of Tech: Rules of Engagement for a Fast Changing Environment
Contents:
White paper

Oncology drug development
and value-based medicine
Brian Huber, Ph.D., Vice President, Innovation, Quintiles
John Doyle, Dr.P.H., M.P.H., Senior Vice President, Consulting at Quintiles

Connecting
insights

Executive summary
An explosion of innovative science, sustained R&D investment and the clinical successes of a new wave
of targeted therapies have transformed the oncology landscap ... See more

Recent Presentations

Jeff Olsen MD
15 December, 2017
...
14 December, 2017
...
13 December, 2017